BEAMER

Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare
Ongoing | IMI2 |
BEAMER logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 23
Grant agreement number
101034369

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
5 948 903
EFPIA in kind
5 590 008
Associated Partners
356 000
Other
1
Total Cost
11 894 912

Summary

Around half of all patients do not take their treatment as prescribed. This ‘non-adherence’ to treatment can have a dramatic impact on patients’ health and quality of life, resulting in avoidable hospitalisations and contributing to an estimated 200 000 deaths annually in the EU.

Currently, we do not fully understand all the factors that influence patients’ decisions regarding their treatments. The BEAMER project aims to add to our understanding of the factors that influence patient adherence across disease areas, and deliver guidance that various stakeholders could use to address patients’ needs and boost adherence.

The project will create a model of the main factors affecting patient adherence to treatment and test it in pilot studies involving 18 000 patients in 6 countries. This will allow the project team to define non-adherence and develop guidance that healthcare stakeholders could transform into tools and solutions to improve adherence. The model will not be disease specific, but it will be possible for users to add disease-specific elements. This will make the model more widely applicable to different groups of patients.

Participants Show participants on map

EFPIA companies
  • Astellas Pharma Europe BV, Leiden, Netherlands
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Servier Affaires Medicales, Suresnes, France
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Akershus Universitetssykehus Hf, Lorenskog, Norway
  • Echalliance Company Limited By Guarantee, Dublin, Ireland
  • Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece
  • Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain
  • Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany
  • Klinikum Der Universitaet Zu Koeln, Cologne, Germany
  • Servicio Madrileno De Salud, Madrid, Spain
  • Stichting Katholieke Universiteit Brabant, Tilburg, Netherlands
  • Udg Alliance, Lausanne, Switzerland
  • Universidad Politecnica De Madrid, Madrid, Spain
  • Universidade Do Porto, Porto, Portugal
  • Universitetet I Oslo, Oslo, Norway
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany
  • Innovation Sprint, Bruxelles, Belgium
  • Medida - Servicos Em Medicina, Educacao, Investigacao, Desenvolvimento E Avaliacao, Porto, Portugal
  • Mysphera SL, Paterna, Spain
  • Open Evidence, Barcelona, Spain
Patient organisations
  • Associacao Protectora Dos Diabeticos De Portugal, Lisboa, Portugal
  • Fondazione Italiana Sclerosi Multipla Fism Onlus, Genoa, Italy
  • Stichting United Parent Projects Muscular Dystrophy, Veenendaal, Netherlands
Associated partners
  • Link2trials BV, Hilversum, Netherlands
Third parties
  • Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus, Madrid, Spain
  • Fundación Para La Investigación E Innovación Biosanitaria De Atención Primaria, Madrid, Spain
Project coordinator
Elísio Costa
Universidade Do Porto